Get the Stockscreener App
14.15
4.58%
0.62
After Hours:
13.92
-0.23
-1.63%
Certara Inc stock is traded at $14.15, with a volume of 2.11M.
It is up +4.58% in the last 24 hours and up +28.17% over the past month.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
See More
Previous Close:
$13.53
Open:
$13.56
24h Volume:
2.11M
Relative Volume:
1.22
Market Cap:
$2.33B
Revenue:
$363.55M
Net Income/Loss:
$-78.68M
P/E Ratio:
-28.30
EPS:
-0.5
Net Cash Flow:
$50.74M
1W Performance:
+34.63%
1M Performance:
+28.17%
6M Performance:
+22.30%
1Y Performance:
-16.52%
1-Day Range:
$13.43
$14.17
1-Week Range:
$11.44
$14.48
52-Week Range:
$8.635
$17.94
Certara Inc Stock (CERT) Company Profile
Name
Certara Inc
Sector
Industry
Phone
(415) 237-8272
Address
4 RADNOR CORPORATE CENTER, SUITE 350, RADNOR
Compare CERT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CERT
Certara Inc
|
14.15 | 2.33B | 363.55M | -78.68M | 50.74M | -0.50 |
|
VEEV
Veeva Systems Inc
|
215.95 | 36.39B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
53.21 | 9.87B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
40.45 | 7.46B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
84.52 | 7.21B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
36.45 | 6.30B | 906.14M | -52.62M | 89.62M | -0.3621 |
Certara Inc Stock (CERT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Upgrade | UBS | Neutral → Buy |
| Apr-10-24 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Apr-04-24 | Initiated | JMP Securities | Mkt Perform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | UBS | Neutral |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Aug-22-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-10-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-23 | Initiated | Stephens | Overweight |
| Apr-03-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-08-22 | Initiated | Berenberg | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jul-01-22 | Initiated | Piper Sandler | Overweight |
| Jan-11-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Jul-23-21 | Initiated | Robert W. Baird | Outperform |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jan-06-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Neutral |
| Jan-05-21 | Initiated | Jefferies | Hold |
| Jan-05-21 | Initiated | William Blair | Outperform |
View All
Certara Inc Stock (CERT) Latest News
Will Certara (CERT) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Certara Inc (CERT) Shares Gap Down to $13.69 on Apr 15 - GuruFocus
Certara expects Q1 sales above estimates - MSN
Top 3 Health Care Stocks You May Want To Dump This Quarter - Benzinga
Certara, Inc.'s (NASDAQ:CERT) 32% Price Boost Is Out Of Tune With Revenues - simplywall.st
Certara (CERT) Exceeds Revenue Expectations with Strong Q1 Growt - GuruFocus
Certara (CERT) Explores Strategic Options for Regulatory Services Unit | CERT Stock News - GuruFocus
Why Certara Inc. (CERT) Soared Last Week? - MSN
Why Certara Inc. (CERT) Skyrocketed On Monday? - MSN
Certara (CERT) Secures One-Year Lock-Up Agreement with Arsenal C - GuruFocus
Certara's Stock Soars on Strong Revenue Guidance and AI-Driven Innovations - GuruFocus
Certara launches Non-Animal Navigator for drug development By Investing.com - Investing.com South Africa
Certara announces Q1 revenue growth and $100 million buyback By Investing.com - Investing.com South Africa
Certara Unveils $100 Million Buyback Plan In Better-Than-Expected Preliminary Earnings Report - Benzinga
Certara Launches Product for Biopharmaceutical Firms to Reduce Reliance on Animal Testing - MarketScreener
Certara IncEntered Into Amendment To Previously Disclosed Letter Agreement Between Co And Arsenal Saturn Holdings Lp - MarketScreener
Certara launches Non-Animal Navigator for drug development - Investing.com Australia
Certara (CERT) Introduces Non-Animal Navigator to Advance Precli - GuruFocus
Certara (CERT) Reaffirms 2025 Financial Projections | CERT Stock News - GuruFocus
Certara Launches Non-Animal Navigator™ Solution to Help Drug Dev - GuruFocus
Certara's Preliminary Q1 Revenue Increases; Reiterates 2025 Outlook; Authorizes $100 Million Share Buyback Plan - MarketScreener
Certara (CERT) Reports Strong Growth in Q1 2024 Performance | CE - GuruFocus
Certara Launches Non-Animal Navigator™ Solution to Help Drug Developers Reduce Reliance on Animal Testing - MarketScreener
Certara Launches Non- Animal Navigator?? Solution to Help Drug Developers Reduce Reliance on Animal Testing - MarketScreener
Certara announces Q1 revenue growth and $100 million buyback - Investing.com
Certara Reports Preliminary First Quarter 2025 Financial Results; Announces $100 Million Share Repurchase Authorization - The Manila Times
Certara Delivers Strong Q1: Software Revenue Surges 18%, Unveils Major Buyback Plan - Stock Titan
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio? - Benzinga
Robert W. Baird Raises Certara (NASDAQ:CERT) Price Target to $13.00 - Defense World
10 Firms Defy Market Slump, Record Double-Digit Gains Last Week - Insider Monkey
Certara Inc (CERT) Shares Up 18.36% on Apr 11 - GuruFocus
Certara (CERT) Receives Price Target Boost Following FDA Biosimu - GuruFocus
Barclays Has Lowered Expectations for Certara (NASDAQ:CERT) Stock Price - Defense World
Certara (NASDAQ:CERT) Shares Gap Up After Analyst Upgrade - Defense World
Why Certara Inc. (CERT) Surged On Friday? - MSN
Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks - Insider Monkey
What Analysts Are Saying About Certara Stock - Benzinga
Certara (CERT) Enhances Simcyp Simulator for Advanced Drug Devel - GuruFocus
Buy Certara After The FDA Announcement (NASDAQ:CERT) - Seeking Alpha
Certara’s Stock: A Rapid Ascent - timothysykes.com
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday? - Benzinga
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday - Benzinga
Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock? - Yahoo Finance
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
After-Hour Gains Boost Certara Stock Following Continued Upward Momentum - Stocks Telegraph
Certara (CERT) Stock Analysis: Is It Overvalued? - GuruFocus
Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements - Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Barclays Remains a Hold on Certara (CERT) - The Globe and Mail
Certara, Inc. (NASDAQ:CERT) Shares Sold by JPMorgan Chase & Co. - Defense World
Certara, Inc. (NASDAQ:CERT) Stock Holdings Lifted by Vanguard Group Inc. - Defense World
Certara Inc Stock (CERT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.14%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):